BriaCell Therapeutics Files 8-K
Ticker: BCTXZ · Form: 8-K · Filed: Jul 18, 2024 · CIK: 1610820
Sentiment: neutral
Topics: sec-filing, 8-k, disclosure
Related Tickers: BCTX
TL;DR
BriaCell filed an 8-K, likely with updates. Stay tuned.
AI Summary
On July 18, 2024, BriaCell Therapeutics Corp. filed an 8-K report. The filing primarily concerns Regulation FD Disclosure and Financial Statements and Exhibits. No specific financial figures or material events were detailed in the provided excerpt.
Why It Matters
This filing indicates BriaCell Therapeutics Corp. is providing updates or disclosures to the SEC, which could contain material information for investors.
Risk Assessment
Risk Level: low — The provided text is a standard SEC filing header and does not contain specific operational or financial risks.
Key Players & Entities
- BriaCell Therapeutics Corp. (company) — Registrant
- July 18, 2024 (date) — Date of Report
- Ansell Capital Corp. (company) — Former Company Name
FAQ
What is the primary purpose of this 8-K filing for BriaCell Therapeutics Corp.?
The filing is primarily for Regulation FD Disclosure and to report Financial Statements and Exhibits.
When was this 8-K report filed?
The report was filed on July 18, 2024.
What was BriaCell Therapeutics Corp.'s former company name?
BriaCell Therapeutics Corp.'s former company name was Ansell Capital Corp.
In which jurisdiction was BriaCell Therapeutics Corp. incorporated?
BriaCell Therapeutics Corp. was incorporated in British Columbia.
What is the principal business address of BriaCell Therapeutics Corp.?
The principal business address is Suite 300 - 235 15th Street West Vancouver, BC V7T 2X1.
Filing Stats: 559 words · 2 min read · ~2 pages · Grade level 10.8 · Accepted 2024-07-18 16:30:28
Filing Documents
- form8-k.htm (8-K) — 40KB
- ex99-1.htm (EX-99.1) — 28KB
- ex99-1_001.jpg (GRAPHIC) — 4KB
- ex99-1_002.jpg (GRAPHIC) — 50KB
- 0001493152-24-028343.txt ( ) — 364KB
- bctx-20240718.xsd (EX-101.SCH) — 4KB
- bctx-20240718_def.xml (EX-101.DEF) — 26KB
- bctx-20240718_lab.xml (EX-101.LAB) — 36KB
- bctx-20240718_pre.xml (EX-101.PRE) — 25KB
- form8-k_htm.xml (XML) — 6KB
SIGNATURES
SIGNATURES Pursuant to the requirements of the Securities Exchange Act of 1934, the registrant has duly caused this report to be signed on its behalf by the undersigned hereunto duly authorized. BRIACELL THERAPEUTICS CORP. /s/ William V. Williams July 18, 2024 William V. Williams President and Chief Executive Officer